TheNote.app
STAT | Reporting from the frontiers of health and medicine

STAT+: Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance

The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new agency officials
favicon
statnews.com
statnews.com
Image for the article: STAT+: Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance
RSS Hunter
© 2015-2025, TheNote.app
· Privacy Policy · Terms & Conditions · Contact · Android iOS MacOS